Spero Therapeutics Q4 2023 GAAP EPS $0.96 Beats $(0.10) Estimate, Sales $73.524M Beat $18.633M Estimate
Spero Therapeutics Q4 2023 GAAP EPS $0.96 Beats $(0.10) Estimate, Sales $73.524M Beat $18.633M Estimate
Spero Therapeutics 2023年第四季度GAAP每股收益爲0.96美元，超過預期（0.10美元），銷售額爲7,352.4萬美元超過預期的1,8633萬美元
Spero Therapeutics (NASDAQ:SPRO) reported quarterly earnings of $0.96 per share which beat the analyst consensus estimate of $(0.10) by 1060 percent. This is a 74.55 percent increase over earnings of $0.55 per share from the same period last year. The company reported quarterly sales of $73.524 million which beat the analyst consensus estimate of $18.633 million by 294.58 percent. This is a 54.98 percent increase over sales of $47.441 million the same period last year.
Spero Therapeutics（納斯達克股票代碼：SPRO）公佈的季度收益爲每股0.96美元，比分析師普遍預期的0.10美元（0.10美元）高出1060％。這比去年同期每股收益0.55美元增長了74.55％。該公司公佈的季度銷售額爲7352.4萬美元，比分析師共識估計的1863.3萬美元高出294.58％。這比去年同期的474.41萬美元的銷售額增長了54.98％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。